Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design
- PMID: 33081503
- PMCID: PMC8252909
- DOI: 10.1089/end.2020.0776
Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design
Abstract
Background: Ureteral stents are commonly employed after ureteroscopy to treat urinary stone disease, but the devices impose a substantial burden of stent-associated symptoms (SAS), including pain and urinary side effects. The NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) Urinary Stone Disease Research Network sought to develop greater understanding of SAS causes and severity among individuals treated ureteroscopically for ureteral or renal stones. Materials and Methods: We designed a prospective, observational cohort study comprising adolescents and adults undergoing ureteroscopic intervention for ureteral or renal stones. Participants will undergo detailed symptom assessment using validated questionnaires, a psychosocial assessment, and detailed collection of clinical and operative data. Quantitative sensory testing will be utilized to assess pain sensitization. In addition, a small cohort (∼40 individuals) will participate in semi-structured interviews to develop more granular information regarding their stent symptoms and experience. Biospecimens (blood and urine) will be collected for future research. Results: The Study to Enhance Understanding of sTent-associated Symptoms (STENTS) enrolled its first participant in March 2019 and completed nested qualitative cohort follow-up in August 2019. After a planned pause, enrollment for the main study cohort resumed in September 2019 and is expected to be completed in 2021. Conclusion: STENTS is expected to provide important insights into the mechanisms and risk factors for severe ureteral SAS after ureteroscopy. These insights will generate future investigations to mitigate the burden of SAS among individuals with urinary stone disease.
Keywords: stent-associated symptoms; ureteral stents; ureteroscopy; urinary stone disease.
Conflict of interest statement
Dr. Antonelli reported relationships with the following entities: Boston Scientific Corp, Cook Medical (Advisory Board). Dr. Tasian reported relationships with the following entities: Dicerna (advisory board, scientific study), Alnylam (advisory board), Novome (advisory board), and Allena Pharmaceuticals (consultant). No other authors reported disclosures relevant to this article.
Figures
References
-
- Assimos DG, Krambeck AE, Miller NL, et al. . Surgical management of stones: American Urological Association/Endourological Society guideline. 2016. Available at: www.auanet.org/guidelines/kidney-stones-surgical-management-guideline
-
- Matlaga BR, Meckley LM, Kim M, Byrne TW. Management patterns of medicare patients undergoing treatment for upper urinary tract calculi. J Endourol 2014;28:723–728 - PubMed
-
- Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: Evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065–1069 - PubMed
-
- Pengfei S, Yutao L, Jie Y, et al. . The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: A systematic review and meta-analysis. J Urol 2011;186:1904–1909 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources